Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.44 |
| ▸ | IDH1 | O75874 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | FAP | Q12884 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 6/20 | 0.35 |
| ▸ | PPARD | Q03181 | 6/20 | 0.35 |
| ▸ | PPARA | Q07869 | 6/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.35 |
| ▸ | TSHR | P16473 | 4/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TLR2 | O60603 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | FABP4 | P15090 | 2/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.35 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9476266 | 0.98 | CCR2 (0.43) | CCR2IDH1PPARGPPARDPPARA | |
| SCHEMBL9477120 | 0.98 | CCR2 (0.43) | CCR2IDH1PPARGPPARDPPARA | |
| Hydrochloric Acid SCHEMBL11038223 | 0.98 | CCR2 (0.43) | CCR2IDH1DPP4FAPDPP7 | |
| SCHEMBL9476457 | 0.98 | CCR2 (0.43) | CCR2IDH1PPARGPPARDPPARA | |
| SCHEMBL9479868 | 0.98 | CCR2 (0.43) | CCR2IDH1PPARGPPARDPPARA | |
| SCHEMBL28827324 | 0.98 | CCR2 (0.43) | CCR2IDH1DPP4FAPDPP7 | |
| SCHEMBL9652423 | 0.98 | CCR2 (0.43) | CCR2IDH1PPARGPPARDPPARA | |
| SCHEMBL10336598 | 0.94 | CCR2 (0.39) | CCR2IDH1DPP4FAPDPP7 | |
| SCHEMBL3375229 | 0.85 | CYP4F2 (0.33) | CCR2CYP4F2CYP4A11 | |
| SCHEMBL20162490 | 0.85 | CYP4F2 (0.33) | CCR2CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | claimed |
| WO-2024167565-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | PURDUE RESEARCH FOUNDATION (US) | 2024-08-15 | — | — | WO | claimed |
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-09-11 | — | — | US | claimed |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | Indiana University Research and Technology Corpora tion (US) | 2016-06-23 | — | — | US | claimed |
| US-9217012-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-12-22 | — | — | US | claimed |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATI (US) | 2012-04-12 | — | — | US | claimed |
| WO-2010118241-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2010-10-14 | — | — | WO | claimed |
| US-7732625-B2 | Colorant compounds | XEROX CORPORATION (US) | 2010-06-08 | — | — | US | claimed |
| EP-1620869-B1 | DYE SENSITIZED SOLAR CELL | ECOLE POLYTECH (CH) | 2009-07-29 | — | — | EP | claimed |
| US-20080006322-A1 | Dye sensitized solar cell | ECOLE POLYTECHNIQUE FEDERAL DE LAUSANNE (EPFL) (CH) | 2008-01-10 | — | — | US | claimed |
| US-7311767-B2 | Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens | XEROX CORPORATION (US) | 2007-12-25 | — | — | US | claimed |
| US-20060021546-A1 | Processes for preparing phase change inks | XEROX CORPORATION | 2006-02-02 | — | — | US | claimed |
| US-20060020141-A1 | Metallized dye | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-20060016369-A1 | PHASE CHANGE INKS | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-6946025-B2 | Process for preparing tetra-amide compounds | XEROX CORPORATION (US) | 2005-09-20 | — | — | US | claimed |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | XEROX CORPORATION | 2005-04-28 | — | — | US | claimed |
| EP-1473745-A1 | Dye sensitized solar cell | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2004-11-03 | — | — | EP | claimed |
| EP-1324997-A2 | DIOXOLANE ANALOGS FOR IMPROVED INTER-CELLULAR DELIVERY | Shire Biochem Inc. (CA) | 2003-07-09 | — | — | EP | claimed |
| WO-2002030922-A2 | DIOXOLANE ANALOGS FOR IMPROVED INTER-CELLULAR DELIVERY | SHIRE BIOCHEM INC. (CA) | 2002-04-18 | — | — | WO | claimed |
| US-12551555-B2 | Compositions and methods for potentiating immune activity | KUMQUAT BIOSCIENCES INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-3965738-B1 | METHOD FOR PRODUCTION OF LIPOSOMES | UNIV DO MINHO (PT) | 2025-08-06 | — | — | EP | disclosed |
| WO-2024167565-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | PURDUE RESEARCH FOUNDATION (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20230107538-A1 | CYCLOALKYL-CONTAINING CARBOXYLIC ACIDS AND USES THEREOF | Liminal Biosciences Limited (GB) | 2023-04-06 | — | — | US | disclosed |
| US-20230107538-A1 | CYCLOALKYL-CONTAINING CARBOXYLIC ACIDS AND USES THEREOF | Liminal Biosciences Limited (GB) | 2023-04-06 | — | — | US | disclosed |
| US-20230044323-A1 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE ACTIVITY | KUMQUAT BIOSCIENCES INC. | 2023-02-09 | — | — | US | disclosed |
| EP-4076649-A1 | CYCLOALKYL-CONTAINING CARBOXYLIC ACIDS AND USES THEREOF | Liminal Biosciences Limited (GB) | 2022-10-26 | — | — | EP | disclosed |
| EP-4073242-A1 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE ACTIVITY | Kumquat Biosciences Inc. (US) | 2022-10-19 | — | — | EP | disclosed |
| CN-115103907-A | Compositions and methods for enhancing immune activity | 金橘生物科技公司 | 2022-09-23 | — | — | CN | disclosed |
| US-20220241203-A1 | METHOD FOR PRODUCTION OF LIPOSOMES | UNIVERSIDADE DO MINHO (PT) | 2022-08-04 | — | — | US | disclosed |
| CN-114828958-A | Cycloalkyl-containing carboxylic acids and use thereof | 里米诺生物科学有限公司 | 2022-07-29 | — | — | CN | disclosed |
| WO-2021124272-A1 | CYCLOALKYL-CONTAINING CARBOXYLIC ACIDS AND USES THEREOF | Liminal Biosciences Limited (GB) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021124272-A1 | CYCLOALKYL-CONTAINING CARBOXYLIC ACIDS AND USES THEREOF | Liminal Biosciences Limited (GB) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021119554-A1 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE ACTIVITY | KUMQUAT BIOSCIENCES INC. (US) | 2021-06-17 | — | — | WO | disclosed |
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-09-11 | — | — | US | disclosed |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | Indiana University Research and Technology Corpora tion (US) | 2016-06-23 | — | — | US | disclosed |
| EP-2766349-B1 | OXATHIAZINE DERIVATIVES SUBSTITUTED WITH CARBOCYCLES OR HETEROCYCLES, METHOD FOR PRODUCING SAME, DRUGS CONTAINING SAID COMPOUNDS, AND USE THEREOF | SANOFI SA (FR) | 2016-06-01 | — | — | EP | disclosed |
| US-9340574-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-05-17 | — | — | US | disclosed |
| US-9337435-B2 | Dye sensitized solar cell | ECOLE POLYTECHNIQUE FEDERAL DE LAUSANNE (EPFL) (CH) | 2016-05-10 | — | — | US | disclosed |
| US-9217012-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-12-22 | — | — | US | disclosed |
| US-20150337013-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | MERCK SHARP & DOHME CORP. (US) | 2015-11-26 | — | — | US | disclosed |
| US-20150239931-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION | 2015-08-27 | — | — | US | disclosed |
| US-9115169-B2 | Method of treating tumors | LYTIX BIOPHARMA AS (NO) | 2015-08-25 | — | — | US | disclosed |
| US-9109048-B2 | Inhibition of tumor growth | LYTIX BIOPHARMA AS (NO) | 2015-08-18 | — | — | US | disclosed |
| US-8901114-B2 | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof | SANOFI (FR) | 2014-12-02 | — | — | US | disclosed |
| WO-2014055768-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2014-04-10 | — | — | WO | disclosed |
| US-20140073558-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CUBIST PHARMACEUTICALS, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140037657-A1 | INHIBITION OF TUMOR GROWTH | LYTIX BIOPHARMA AS (NO) | 2014-02-06 | — | — | US | disclosed |
| US-20130345128-A1 | OXATHIAZINE DERIVATIVES SUBSTITUTED WITH CARBOCYCLES OR HETEROCYCLES, METHOD FOR PRODUCING SAME, DRUGS CONTAINING SAID COMPOUNDS, AND USE THEREOF | SANOFI (FR) | 2013-12-26 | — | — | US | disclosed |
| EP-2674437-A1 | Novel antibacterial agents for the treatment of GRAM positive infections | Cubist Pharmaceuticals, Inc. (US) | 2013-12-18 | — | — | EP | disclosed |
| EP-2379580-B1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CUBIST PHARM INC (US) | 2013-10-23 | — | — | EP | disclosed |
| US-8507647-B2 | Antibacterial agents for the treatment of gram positive infections | CUBIST PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8440843-B2 | 2, 2-bipyridine ligand, sensitizing dye and dye sensitized solar cell | ECOLE POLYTECHNIQUE FéDéRALE DE LAUSANNE (CH) | 2013-05-14 | — | — | US | disclosed |
| US-8283315-B2 | Inhibition of tumour growth | LYTIX BIOPHARMA AS (NO) | 2012-10-09 | — | — | US | disclosed |
| US-20120108520-A1 | Antimicrobial Compounds and Formulations | LYTIX BIOPHARMA AS (NO) | 2012-05-03 | — | — | US | disclosed |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATI (US) | 2012-04-12 | — | — | US | disclosed |
| US-8143211-B2 | Bioactive peptides | LYTIX BIOPHARMA AS (NO) | 2012-03-27 | — | — | US | disclosed |
| US-8048852-B2 | Antimicrobial compounds and formulations | LYTIX BIOPHARMA AS (NO) | 2011-11-01 | — | — | US | disclosed |
| EP-2379580-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | Cubist Pharmaceuticals, Inc. (US) | 2011-10-26 | — | — | EP | disclosed |
| EP-1263471-B1 | ANTIMICROBIAL COMPOUNDS AND FORMULATIONS | LYTIX BIOPHARMA AS (NO) | 2011-10-12 | — | — | EP | disclosed |
| US-8026264-B2 | Triazole derivatives as inhibitors of 11-β hydroxysteroid dehydrogenase-1 | MERCK SHARP AND DOHME CORP. (US) | 2011-09-27 | — | — | US | disclosed |
| US-8026264-B2 | Triazole derivatives as inhibitors of 11-β hydroxysteroid dehydrogenase-1 | MERCK SHARP AND DOHME CORP. (US) | 2011-09-27 | — | — | US | disclosed |
| US-8026264-B2 | Triazole derivatives as inhibitors of 11-β hydroxysteroid dehydrogenase-1 | MERCK SHARP AND DOHME CORP. (US) | 2011-09-27 | — | — | US | disclosed |
| US-20110190501-A1 | 2, 2-Bipyridine ligand, sensitizing dye and dye sensitized solar cell | Ecole polytechnique fédérale de Lausanne (EPFL) | 2011-08-04 | — | — | US | disclosed |
| EP-2338522-A1 | Antitumoural therapies | Lytix Biopharma AS (NO) | 2011-06-29 | — | — | EP | disclosed |
| EP-1109827-B1 | BIOACTIVE PEPTIDES | LYTIX BIOPHARMA AS (NO) | 2011-06-22 | — | — | EP | disclosed |
| US-7932404-B2 | 2,2-bipyridine ligand, sensitizing dye and dye sensitized solar cell | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2011-04-26 | — | — | US | disclosed |
| EP-1109831-B1 | CYCTOTOXIC PEPTIDES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES | LYTIX BIOPHARMA AS (NO) | 2011-01-12 | — | — | EP | disclosed |
| EP-1956054-B1 | Phase change ink | XEROX CORP (US) | 2010-11-24 | — | — | EP | disclosed |
| US-20100267621-A1 | Antimicrobial Compounds and Formulations | LYTIX BIOPHARMA AS (NO) | 2010-10-21 | — | — | US | disclosed |
| WO-2010118241-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
| EP-2228364-A1 | Acylsulfonamides as inhibitors of steroid sulfatase | Novartis AG (CH) | 2010-09-15 | — | — | EP | disclosed |
| EP-1638947-B1 | TRIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA HYDROXYSTEROID DEHYDROGENASE-1 | MERCK SHARP & DOHME (US) | 2010-08-04 | — | — | EP | disclosed |
| EP-1638947-B1 | TRIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA HYDROXYSTEROID DEHYDROGENASE-1 | MERCK SHARP & DOHME (US) | 2010-08-04 | — | — | EP | disclosed |
| US-20100184649-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CUBIST PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
| WO-2010075215-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CUBIST PHARMACEUTICALS, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
| US-7732625-B2 | Colorant compounds | XEROX CORPORATION (US) | 2010-06-08 | — | — | US | disclosed |
| US-20090227620-A1 | ANTI-INFLAMMATORY COMPOUNDS | MEINGASSNER JOSEF GOTTFRIED | 2009-09-10 | — | — | US | disclosed |
| US-20090181994-A1 | TRIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK & CO., INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-20090181994-A1 | TRIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK & CO., INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-20090181994-A1 | TRIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK & CO., INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-7504402-B2 | Triazole derivatives as inhibitors of 11-β-hydroxysteroid dehydrogenase-1 | MERCK & CO., INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7504402-B2 | Triazole derivatives as inhibitors of 11-β-hydroxysteroid dehydrogenase-1 | MERCK & CO., INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7504402-B2 | Triazole derivatives as inhibitors of 11-β-hydroxysteroid dehydrogenase-1 | MERCK & CO., INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7482462-B2 | Acylsulfonamides as inhibitors of steroid sulfatase | NOVARTIS AG (CH) | 2009-01-27 | — | — | US | disclosed |
| US-20090000658-A1 | 2,2-Bipyridine Ligand, Sensitizing Dye and Dye Sensitized Solar Cell | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2009-01-01 | — | — | US | disclosed |
| US-20080293758-A1 | Combination of a Steroid Sulfatase Inhibitor and an Ascomycin | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
| US-20080287346-A1 | Bioactive peptides | SVENDSEN JOHN SIGURD | 2008-11-20 | — | — | US | disclosed |
| US-7439228-B2 | Bioactive peptides | LYTIX BIOPHARMA AS (NO) | 2008-10-21 | — | — | US | disclosed |
| EP-1958993-A1 | Phase change inks containing colorant compounds | Xerox Corporation (US) | 2008-08-20 | — | — | EP | disclosed |
| EP-1956054-A2 | Colorant compounds | Xerox Corporation (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20080187664-A1 | Phase change inks containing colorant compounds | XEROX CORPORATION | 2008-08-07 | — | — | US | disclosed |
| US-20080184910-A1 | Mixture of basic dye and wax | XEROX CORPORATION | 2008-08-07 | — | — | US | disclosed |
| US-20080019993-A1 | Inhibition of tumour growth | LYTIX BIOPHARMA AS (NO) | 2008-01-24 | — | — | US | disclosed |
| US-7311767-B2 | Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens | XEROX CORPORATION (US) | 2007-12-25 | — | — | US | disclosed |
| EP-1861098-A1 | ANTI-INFLAMMATORY COMPOUNDS | Novartis AG (CH) | 2007-12-05 | — | — | EP | disclosed |
| EP-1861099-A2 | COMBINATION OF A STEROID SULFATASE INHIBITOR AND AN ASCOMYCIN | Novartis AG (CH) | 2007-12-05 | — | — | EP | disclosed |
| EP-1638947-A4 | TRIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA HYDROXYSTEROID DEHYDROGENASE-1 | MERCK & CO INC (US) | 2007-10-31 | — | — | EP | disclosed |
| EP-1581515-B1 | TRIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK & CO INC (US) | 2007-10-10 | — | — | EP | disclosed |
| EP-1581515-B1 | TRIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK & CO INC (US) | 2007-10-10 | — | — | EP | disclosed |
| US-7232803-B2 | Antimicrobial compounds and formulations | LYTIX BIOPHARMA AS (NO) | 2007-06-19 | — | — | US | disclosed |
| US-20060276505-A1 | Acylhydrazine P2X7 antagonists and uses thereof | ABBOTT LABORATORIES | 2006-12-07 | — | — | US | disclosed |
| US-20060258695-A1 | Triazole derivatives as inhibitors of 11-beta hydroxysteroid dehydrogenase-1 | MERCK SHARP & DOHME LLC | 2006-11-16 | — | — | US | disclosed |
| WO-2006110516-A1 | ACYLHYDRAZIDE P2X7 ANTAGONISTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006097293-A2 | COMBINATION OF A STEROID SULFATASE INHIBITOR AND AN ASCOMYCIN | NOVARTIS AG (CH) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006097292-A1 | ANTI-INFLAMMATORY COMPOUNDS | NOVARTIS AG (CH) | 2006-09-21 | — | — | WO | disclosed |
| US-7033424-B2 | Phase change inks | XEROX CORPORATION (US) | 2006-04-25 | — | — | US | disclosed |
| EP-1638947-A2 | TRIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA HYDROXYSTEROID DEHYDROGENASE-1 | Merck & Co., Inc. (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20060021546-A1 | Processes for preparing phase change inks | XEROX CORPORATION | 2006-02-02 | — | — | US | disclosed |
| EP-1581515-A1 | TRIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | Merck & Co., Inc. (US) | 2005-10-05 | — | — | EP | disclosed |
| US-6946025-B2 | Process for preparing tetra-amide compounds | XEROX CORPORATION (US) | 2005-09-20 | — | — | US | disclosed |
| US-20050154038-A1 | Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 | MERCK SHARP & DOHME LLC | 2005-07-14 | — | — | US | disclosed |
| EP-1178969-B1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | BLACK JAMES FOUNDATION (GB) | 2005-07-13 | — | — | EP | disclosed |
| US-6890902-B2 | Cytotoxic modified lactoferrin peptides | ALPHARMA AS (NO) | 2005-05-10 | — | — | US | disclosed |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | XEROX CORPORATION | 2005-04-28 | — | — | US | disclosed |
| US-20050059712-A1 | Acylsulfonamides as inhibitors of steroid sulfatase | NOVARTIS AG (CH) | 2005-03-17 | — | — | US | disclosed |
| US-6849636-B2 | Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 | MERCK & CO., INC. (US) | 2005-02-01 | — | — | US | disclosed |
| EP-0948361-B1 | MAGNETIC RESONANCE BLOOD POOL AGENTS | MALLINCKRODT INC (US) | 2005-01-26 | — | — | EP | disclosed |
| WO-2004106294-A2 | TRIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA HYDROXYSTEROID DEHYDROGENASE-1 | MERCK & CO., INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004058730-A2 | TRIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK & CO., INC. (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004058741-A1 | TRIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK & CO., INC. (US) | 2004-07-15 | — | — | WO | disclosed |
| EP-1436253-A1 | ACYLSULFONAMIDES AS INHIBITORS OF STEROID SULFATASE | Novartis AG (CH) | 2004-07-14 | — | — | EP | disclosed |
| US-20040133011-A1 | Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 | MERCK SHARP & DOHME LLC | 2004-07-08 | — | — | US | disclosed |
| EP-0849634-B1 | Radiation sensitive resin composition | JSR CORP (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-20030195144-A1 | Antimicrobial compounds and formulations | LYTIX BIOPHARMA AS (NO) | 2003-10-16 | — | — | US | disclosed |
| US-20030148936-A1 | Bioactive peptides | ALPHARMA AS. | 2003-08-07 | — | — | US | disclosed |
| WO-2003031397-A1 | ACYLSULFONAMIDES AS INHIBITORS OF STEROID SULFATASE | NOVARTIS AG (CH) | 2003-04-17 | — | — | WO | disclosed |
| US-20030022821-A1 | Bioactive peptides | ALPHARMA AS | 2003-01-30 | — | — | US | disclosed |
| US-20030013660-A1 | Dioxolane analogs for improved inter-cellular delivery | SHIRE BIOCHEM INC. (CA) | 2003-01-16 | — | — | US | disclosed |
| US-6479531-B1 | Gastrin and cholecystokinin receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 2002-11-12 | — | — | US | disclosed |
| EP-1178969-A1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2002-02-13 | — | — | EP | disclosed |
| US-6322949-B2 | SULFONIUM COMPOUND AS PHOTOACID GENERATOR | JAPAN SYNTHETIC RUBBER CO., LTD. (JP) | 2001-11-27 | — | — | US | disclosed |
| US-20010014427-A1 | Radiation sensitive resin composition | JAPAN SYNTHETIC RUBBER CO., LTD. (JP) | 2001-08-16 | — | — | US | disclosed |
| US-6238842-B1 | SUITABLE FOR USE WITH AN EXPOSURE LIGHT HAVING A WAVELENGTH OF 250 NM OR SHORTER, ESPECIALLY 220 NM OR SHORTER; ACID GENERATING COMPOUND; RESIN HAVING MONOVALENT POLYALICYCLIC GROUPS | FUJI PHOTO FILM CO., LTD. (JP) | 2001-05-29 | — | — | US | disclosed |
| US-6187504-B1 | PHOTOSENSITIVE BLEND CONTAINING A NAPHTHALENE SULFONIUM SULFONATE DERIVATIVE PHOTOACID GENERATOR, RESIN HAVING ALKALI INSOLUBLE GROUPS CLEAVABLE BY ACID, AN ALKALI SOLUBLE RESIN AND A SOLUBILITY CONTROL AGENT; POSITIVES, RESOLUTION | JSR CORPORATION (JP) | 2001-02-13 | — | — | US | disclosed |
| EP-0948361-A4 | MAGNETIC RESONANCE BLOOD POOL AGENTS | MALLINCKRODT MEDICAL INC (US) | 2001-02-07 | — | — | EP | disclosed |
| WO-2000027823-A1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2000-05-18 | — | — | WO | disclosed |
| EP-0948361-A1 | MAGNETIC RESONANCE BLOOD POOL AGENTS | MALLINCKRODT MEDICAL, INC. (US) | 1999-10-13 | — | — | EP | disclosed |
| EP-0849634-A1 | Radiation sensitive resin composition | JAPAN SYNTHETIC RUBBER CO., LTD. (JP) | 1998-06-24 | — | — | EP | disclosed |
| WO-1998020908-A1 | MAGNETIC RESONANCE BLOOD POOL AGENTS | MALLINCKRODT MEDICAL, INC. (US) | 1998-05-22 | — | — | WO | disclosed |
| US-5182047-A | FLUORINATED BIPHENYLDIOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 1993-01-26 | — | — | US | disclosed |
| US-4895986-A | CHEMICAL INTERMEDIATE | COMMISSARIAT A L'ENERGIE (FR) | 1990-01-23 | — | — | US | disclosed |
| EP-0309870-A2 | Liquid crystalline compounds containing the bicyclo[2,2,2]-octane ring and the phenylisothiocyanate group, their manufacturing and liquid crystalline mixtures containing same | Wojskowa Akademia Techniczna (PL) | 1989-04-05 | — | — | EP | disclosed |
| US-4795579-A | 2,2'-difluoro-4-alkoxy-4'-hydroxydiphenyls and their derivatives, their production process and their use in liquid crystal display devices | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1989-01-03 | — | — | US | disclosed |
| US-4694098-A | WIDE MESOMORPHIC RANGE | HITACHI, LTD. (JP) | 1987-09-15 | — | — | US | disclosed |
| EP-0058981-B1 | COLORLESS LIQUID CRYSTALLINE COMPOUNDS | Hitachi, Ltd. (JP) | 1986-01-22 | — | — | EP | disclosed |
| US-4564694-A | CYCLOHEXYL AND PHENYL RING-CONTAINING ALIPHATIC ETHERS | HITACHI, LTD. (JP) | 1986-01-14 | — | — | US | disclosed |
| US-4514317-A | A BICYCLO(2,2,2,) OCTANE RING AND DICYANO SUBSTITUTED BENZENE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1985-04-30 | — | — | US | disclosed |
| US-4357078-A | ELECTROOPTICS; DISPLAYING | THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) | 1982-11-02 | — | — | US | disclosed |
| EP-0058981-A2 | Colorless liquid crystalline compounds | Hitachi, Ltd. (JP) | 1982-09-01 | — | — | EP | disclosed |
| EP-0058981-A2 | Colorless liquid crystalline compounds | Hitachi, Ltd. (JP) | 1982-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (32 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345128-A1 | OXATHIAZINE DERIVATIVES SUBSTITUTED WITH CARBOCYCLES OR HETEROCYCLES, METHOD FOR PRODUCING SAME, DRUGS CONTAINING SAID COMPOUNDS, AND USE THEREOF | SLC5A2, SLC5A1, OTC | CCR2 896/4885IDH1 100/4885DPP4 56/4885 |
| US-20120108520-A1 | Antimicrobial Compounds and Formulations | VIP, NONO, CLPTM1 | CCR2 1071/4885IDH1 3817/4885DPP4 198/4885 |
| US-20080293758-A1 | Combination of a Steroid Sulfatase Inhibitor and an Ascomycin | STS, ARSA, CYP17A1 | CCR2 4734/4885IDH1 2314/4885DPP4 379/4885 |
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | PTPRCAP, PTPRF, PTPRS | CCR2 3102/4885IDH1 1570/4885DPP4 853/4885 |
| US-20030013660-A1 | Dioxolane analogs for improved inter-cellular delivery | SLC19A1, SLC29A1, SLC29A2 | CCR2 966/4885IDH1 173/4885DPP4 3337/4885 |
| US-20080287346-A1 | Bioactive peptides | VIP, NGLY1, IAPP | CCR2 1973/4885IDH1 3795/4885DPP4 78/4885 |
| US-20100267621-A1 | Antimicrobial Compounds and Formulations | VIP, NONO, CLPTM1 | CCR2 1071/4885IDH1 3817/4885DPP4 198/4885 |
| US-12551555-B2 | Compositions and methods for potentiating immune activity | PTPRCAP, PTPN2, PTPRC | CCR2 479/4885IDH1 2737/4885DPP4 1843/4885 |
| US-20080019993-A1 | Inhibition of tumour growth | STING1, VIP, MIF | CCR2 1322/4885IDH1 3343/4885DPP4 885/4885 |
| US-20150337013-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CLPP, CLPTM1, RPN1 | CCR2 1240/4885IDH1 4657/4885DPP4 512/4885 |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTPRCAP, PTPRF, PTPRS | CCR2 3102/4885IDH1 1570/4885DPP4 853/4885 |
| US-20100184649-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CLPP, CLPTM1, RPN1 | CCR2 1240/4885IDH1 4657/4885DPP4 512/4885 |
| US-20060020141-A1 | Metallized dye | CDYL, CDY1; CDY1B, CDYL2 | CCR2 863/4885IDH1 330/4885DPP4 2211/4885 |
| US-20090227620-A1 | ANTI-INFLAMMATORY COMPOUNDS | STS, SERPINB1, MPO | CCR2 1761/4885IDH1 3948/4885DPP4 253/4885 |
| US-20230044323-A1 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE ACTIVITY | NFATC1, MYD88, ICOS | CCR2 454/4885IDH1 4319/4885DPP4 3680/4885 |
| US-20090000658-A1 | 2,2-Bipyridine Ligand, Sensitizing Dye and Dye Sensitized Solar Cell | KMO, SUN2, PDCD1LG2 | CCR2 1153/4885IDH1 1888/4885DPP4 4422/4885 |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | TAF9, TAF5, TAF1 | CCR2 3795/4885IDH1 41/4885DPP4 1780/4885 |
| US-20110190501-A1 | 2, 2-Bipyridine ligand, sensitizing dye and dye sensitized solar cell | SUN2, CD4, KMO | CCR2 980/4885IDH1 1899/4885DPP4 4535/4885 |
| US-20060276505-A1 | Acylhydrazine P2X7 antagonists and uses thereof | P2RX7, P2RX3, P2RX1 | CCR2 641/4885IDH1 1247/4885DPP4 520/4885 |
| US-20030148936-A1 | Bioactive peptides | VIP, NGLY1, HM13 | CCR2 1868/4885IDH1 4131/4885DPP4 389/4885 |
| US-20030195144-A1 | Antimicrobial compounds and formulations | LPO, CLPTM1, VIP | CCR2 855/4885IDH1 4226/4885DPP4 234/4885 |
| US-20030022821-A1 | Bioactive peptides | VIP, LITAF, LNPEP | CCR2 3121/4885IDH1 3989/4885DPP4 502/4885 |
| US-20050154038-A1 | Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 | HSD11B1, HSD17B1, HSD3B1 | CCR2 4617/4885IDH1 292/4885DPP4 290/4885 |
| US-20150239931-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTP4A2, PTPRF, PTPA | CCR2 3192/4885IDH1 2523/4885DPP4 117/4885 |
| US-20040133011-A1 | Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 | HSD11B1, HSD17B1, HSD3B1 | CCR2 4637/4885IDH1 289/4885DPP4 313/4885 |
| US-20060258695-A1 | Triazole derivatives as inhibitors of 11-beta hydroxysteroid dehydrogenase-1 | HSD11B1, HSD17B1, HSD3B1 | CCR2 4630/4885IDH1 333/4885DPP4 275/4885 |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTPRCAP, PTPRF, PTPRS | CCR2 3102/4885IDH1 1570/4885DPP4 853/4885 |
| US-20230107538-A1 | CYCLOALKYL-CONTAINING CARBOXYLIC ACIDS AND USES THEREOF | HCCS, CCL11, BCAT1 | CCR2 55/4885IDH1 17/4885DPP4 4324/4885 |
| US-20050059712-A1 | Acylsulfonamides as inhibitors of steroid sulfatase | STS, SULT2A1, ARSA | CCR2 1614/4885IDH1 291/4885DPP4 1469/4885 |
| US-20140073558-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CLPP, CLPTM1, RPN1 | CCR2 1240/4885IDH1 4657/4885DPP4 512/4885 |
| US-20140037657-A1 | INHIBITION OF TUMOR GROWTH | STING1, VIP, MIF | CCR2 1190/4885IDH1 3404/4885DPP4 726/4885 |
| US-20090181994-A1 | TRIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | HSD11B1, HSD17B1, HSD3B1 | CCR2 4617/4885IDH1 292/4885DPP4 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.